Fig. 4.
Optimization of dihydroxypyrimidine (1, 2) and N -methyl pyrimidinone carboxamides (3, 4) as HIV-1 integrase strand transfer inhibitors, which led to the design of raltegravir (inhibitor MK-0518).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.